MARKET

CLSD

CLSD

Clearside Biomed
NASDAQ
1.130
+0.060
+5.61%
After Hours: 1.150 +0.02 +1.77% 19:52 02/07 EST
OPEN
1.100
PREV CLOSE
1.070
HIGH
1.140
LOW
1.060
VOLUME
349.79K
TURNOVER
--
52 WEEK HIGH
2.120
52 WEEK LOW
0.8010
MARKET CAP
85.70M
P/E (TTM)
-2.5094
1D
5D
1M
3M
1Y
5Y
1D
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
Barchart · 4d ago
Weekly Report: what happened at CLSD last week (0127-0131)?
Weekly Report · 5d ago
Clearside Biomedical announces medical meeting presentations on pipeline
TipRanks · 01/28 12:20
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
Barchart · 01/28 06:05
Weekly Report: what happened at CLSD last week (0120-0124)?
Weekly Report · 01/27 09:56
Clearside Biomedical announces ARCATUS approved in Australia, Singapore
TipRanks · 01/22 12:15
CLEARSIDE BIOMEDICAL ANNOUNCES ITS ASIA-PACIFIC PARTNER, ARCTIC VISION, RECEIVED APPROVAL OF SUPRACHOROIDAL TREATMENT FOR UVEITIC MACULAR EDEMA IN AUSTRALIA AND SINGAPORE
Reuters · 01/22 12:05
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
Barchart · 01/22 06:05
More
About CLSD
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

Webull offers Clearside Biomedical Inc stock information, including NASDAQ: CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLSD stock methods without spending real money on the virtual paper trading platform.